Objective: Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes.
Methods: Prospective cohort study of XDR-TB patients on treatment in KwaZulu-Natal, South Africa. Adherence to ARV and TB medications was assessed separately at baseline and monthly. Knowledge, attitudes, and beliefs were assessed at baseline. Optimal adherence was defined as self-report of taking all pills in the previous 7 days; missing any pills was defined as suboptimal adherence. Primary outcome was optimal adherence 6 months after initiation of XDR-TB treatment to TB medications, ARV, and both (“dual adherence”).
Results: One hundred four XDR-TB patients (79.8% HIV coinfected, 84.3% on ARV at enrollment) were enrolled and followed monthly (median 8 visits; interquartile range: 4–12). Six-month optimal adherence was higher for ARV (88.2%) than TB medications (67.7%) (P < 0.001). Low educational attainment, male gender, and year of enrollment were independently associated with dual suboptimal adherence. At baseline, participants indicated that XDR-TB was curable (76.0%), HIV and TB were linked (81.7%), and ARV improves TB outcomes (72.1%). Baseline knowledge, attitudes, and beliefs did not predict subsequent adherence.
Conclusions: Medication adherence was significantly higher for ARV than for TB medications in this cohort. Short-course treatment regimens for drug-resistant TB with lower pill burden may increase adherence and improve outcomes in XDR-TB/HIV. Programmatic support for dual adherence is critical in the treatment of drug-resistant TB and HIV.
*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY;
†Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY;
‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa;
§Department of Epidemiology, Boston University School of Public Health, Boston, MA; and
‖University of KwaZulu-Natal, Durban, South Africa.
Correspondence to: Max R. O'Donnell, MD, MPH, Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University College of Physicians and Surgeons, PH-8 East, Room 101, 622 West 168th Street, New York, NY 10032 (e-mail: email@example.com).
M.R.O. was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (5K23AI098479), Albert Einstein Center for Global Health & Clinical and Translational Research Institute, and Stony-Wold Herbert Fund. M.R.O. and N.P. were supported by the Centre for AIDS Programme of Research in South Africa (CAPRISA).
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
Received February 17, 2014
Accepted May 05, 2014